Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer therapy by biological response modifiers.

R B Herberman

    Arzneimittel-Forschung
    |February 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Biological response modifiers (BRMs) enhance cancer treatment by modulating the host

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Tumor immunology.

    JAMA·1992
    Same author

    The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.

    Cancer research·1992
    Same author

    Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.

    Cancer research·1992
    Same author

    Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role.

    Journal of immunology (Baltimore, Md. : 1950)·1992
    Same author

    Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

    International journal of cancer·1992
    Same author

    Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration.

    Natural immunity·1992
    Same journal

    Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

    Arzneimittel-Forschung·2013
    Same journal

    Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

    Arzneimittel-Forschung·2013
    Same journal

    Leave-one-out procedure in the validation of elimination rate constant analysis.

    Arzneimittel-Forschung·2012
    Same journal

    Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

    Arzneimittel-Forschung·2012
    Same journal

    Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

    Arzneimittel-Forschung·2012
    Same journal

    Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

    Arzneimittel-Forschung·2012
    See all related articles

    Area of Science:

    • Oncology and Immunology

    Background:

    • Biological response modifiers (BRMs) modulate the host-tumor relationship for therapeutic benefit.
    • BRMs encompass immunomodulators, cytokines, antibodies, and effector cells.
    • Optimizing BRM therapy requires understanding mechanisms of action and monitoring treatment effects.

    Purpose of the Study:

    • To summarize the therapeutic potential and challenges of BRMs in cancer treatment.
    • To illustrate these points using examples of interferons and interleukin-2 (IL-2).
    • To propose a new clinical trial sequence for evaluating BRMs, particularly in patients with minimal tumor burden.

    Main Methods:

    • Review of existing data on interferons and IL-2.
    • Analysis of challenges in determining optimal therapeutic regimens for BRMs.
    • Description of a novel clinical trial design for BRM evaluation.

    Related Experiment Videos

    Main Results:

    • Interferons and IL-2 show promise but present difficulties in optimizing treatment.
    • Determining mechanisms of action is crucial for effective BRM therapy.
    • A new trial sequence focuses on patients with minimal tumor burden.

    Conclusions:

    • BRMs offer a promising avenue for cancer therapy.
    • Optimizing BRM treatment requires a deeper understanding of their mechanisms and careful monitoring.
    • New clinical trial designs are needed to effectively evaluate BRMs, especially in early-stage disease.